Navigation Links
Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes
Date:11/17/2009

MADISON, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the determination of the pricing for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 (the "2010 Notes") and any and all of its 7.50% Senior Notes due 2011 (the "2011 Notes" and, together with the 2010 Notes, the "Notes"). Additional terms and conditions of the Tender Offer are set forth in the Offer to Purchase dated November 12, 2009 (the "Offer to Purchase") and the related Letter of Transmittal (the "Letter of Transmittal"). The offer will expire at 5:00 p.m., New York City Time, on November 19, 2009, unless extended (the "Expiration Date").

The Company will pay holders who validly tendered and did not validly withdraw their Notes at or prior to the Expiration Date, the purchase price of $1,037.19 for each $1,000 principal amount of its 2010 Notes accepted for purchase and $1,099.40 for each $1,000 principal amount of its 2011 Notes accepted for purchase, plus, in each case, accrued and unpaid interest up to, but not including, the settlement date.

The purchase price has been determined for each series of Notes by reference to the applicable fixed spread specified for each series of Notes over the yield based on the bid-side price of the applicable U.S. Treasury Security ("Reference Yield"), as calculated by BofA Merrill Lynch, the Global Coordinator & Joint Lead Dealer Manager, at 2:00 p.m., New York City time, on November 17, 2009. The formula for determining the purchase price is set forth in Schedule A of the Offer to Purchase. The purchase prices, the applicable Reference Yields and the accrued and unpaid interest, assuming a settlemen
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
2. VioQuest Pharmaceuticals Completes Enrollment of Phase I Trial of Lenocta(TM)
3. Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
6. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
7. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
8. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
11. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical company, ... developing novel treatments for dry eye disease, today announced ... Allergan will acquire Oculeve in an all-cash transaction.  Under ... for a $125 million upfront payment and commercialization milestone ...
(Date:7/6/2015)... July 6, 2015 /PRNewswire/ -- China Nepstar Chain Drugstore Ltd. ... leading retail drugstore chain in China ... today announced that its board of directors has received ... from Simin Zhang , chairman of the board ... Holding Ltd., an investment vehicle wholly owned by Mr. ...
(Date:7/4/2015)... July 4, 2015 Adding ... patients with unresectable metastatic colorectal cancer in the ... organ Patients with unresectable metastatic colorectal ... liver experienced the greatest improvement in Progression-Free Survival ... SIR-Spheres Y-90 resin microspheres to a current first-line ...
Breaking Medicine Technology:Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 2China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 3China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 4China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 5China Nepstar Chain Drugstore Ltd. Announces Receipt of "Going Private" Proposal 6New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
(Date:7/5/2015)... , ... July 05, 2015 , ... Women’s Excellence ... college) at their Lake Orion location. The special consists of 2 months of unlimited ... Wellness, powered by Movestrong is located at 1410 South Lapeer Road in Lake Orion. ...
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... ... Plastic Surgeons published the results of an annual member survey , detailing ... United States. More recently, the group broke that raw data down into charts ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project Developer of ... expertise from the North American Board of Certified Energy Practitioners (NABCEP®), and is ... respected and well established national certification organization for renewable energy professionals. Designation as ...
(Date:7/3/2015)... ... , ... On June 30th SEO authority and veteran Internet ... "Page One Engine" . The program, which has been hailed as the ... well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, publishing an in-depth review ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Renowned rhinoplasty ... dates for the 2016 Dallas Rhinoplasty Symposium . To be held from March ... meeting will be held at the Westin Galleria Dallas. , Designed to take participants ...
Breaking Medicine News(10 mins):Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3
... earthquake to ravage China in decades, the task of ... onerous one. The 7.9-magnitude earthquake of 12 May devastated ... and causing extensive property damage. , Among the many ... enemy stray radioactive sources that could complicate relief ...
... 2008: Low bone mineral density in the hand is ... rheumatoid arthritis (RA) and indicates long-term prognosis, according to ... Annual Congress of the European League Against Rheumatism in ... density to be as effective predicting mortality as well-established ...
... France June 12, 2008 -- Biogen Idec ... the first dual-mechanism, lymphotoxin-; (LT-;) and LIGHT pathway ... diseases, including rheumatoid arthritis (RA), during the 2008 ... of Rheumatology at the Le Palais de Congrs ...
... Sales Already Exceed Q1 2008 and Q2 2007 Levels, - ... ... Surgeons, MONROVIA, Calif., June 12 STAAR ... invasive ophthalmic products, today announced that Visian ICL(TM),(Implantable Collamer Lens) sales in ...
... Laurent Claret Will Present Case Studies on the ... and Survival Benefits of Anticancer Agents, MOUNTAIN ... PHST ), a leading provider of software, strategic,consulting, ... announced that Laurent Claret, Ph.D., senior scientist,Pharsight Strategic ...
... A research abstract that will be presented on ... the Associated Professional Sleep Societies (APSS), finds a link ... adolescents with depressive episodes. , The study, authored by ... Brazil, focused on 303 individuals with pediatric bipolar disorder ...
Cached Medicine News:Health News:In quake's aftermath, Chinese sift through rubble for radioactivity 2Health News:Hand bone mineral density is an effective predictor of mortality in rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 2Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 3Health News:Biogen Idec's baminercept alfa shows promise in patients with rheumatoid arthritis 4Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 2Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 3Health News:STAAR Surgical's LASIK Alternative Expands U.S. Market Gains 4Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 2Health News:Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting 3Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 2Health News:Poor sleep linked to suicidal behavior among children and adolescents with depressive episodes 3
... OMNISCAN was launched in the U.S. in ... central nervous system (CNS) to detect lesions ... tissues. OMNISCAN has since received approval for ... pediatric CNS and body indications. OMNISCAN comes ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
... only isosmolar contrast medium (IOCM) available in the ... blood, VISIPAQUE was designed for patient safety and ... formulated with sodium and calcium in a ratio ... approval for use in children over one year ...
Medicine Products: